Quest for cancer biomarkers: Assaying mutant proteins and RNA that provides the much needed specificity

Journal of Proteomics and Bioinformatics

Volumn 5, Issue 11, 2012, Pages

  Mathivanan, Suresh ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; TUMOR MARKER;

AREA UNDER THE CURVE; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; COLON CANCER; DISEASE COURSE; EARLY DIAGNOSIS; EDITORIAL; ENDOPLASMIC RETICULUM; GENE MUTATION; HUMAN; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN SECRETION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TISSUE HOMOGENATE; TOPOGRAPHY;

EID: 84870665585     PISSN: None     EISSN: 0974276X     Source Type: Journal    
DOI: 10.4172/jpb.10000e16     Document Type: Editorial

References (63)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
3. Xue H, Lu B, Lai M (2008) The cancer secretome: a reservoir of biomarkers. J Transl Med 6: 52.
4. O'Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420-1425.
5. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, et al. (2003) The case for early detection. Nat Rev Cancer 3: 243-252.
6. Diamandis EP, van der Merwe DE (2005) Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 11: 963-965.
7. Hanash SM, Pitteri SJ, Faca VM (2008) Mining the plasma proteome for cancer biomarkers. Nature 452: 571-579.
8. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24: 971-983.
9. Sawyers CL (2008) The cancer biomarker problem. Nature 452: 548-552.
10. Chin L, Gray JW (2008) Translating insights from the cancer genome into clinical practice. Nature 452: 553-563.
11. Nowell PC (2007) Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 117: 2033-2035.
12. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbBrelated gene in a human mammary carcinoma. Science 229: 974-976.
13. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124.
14. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444.
15. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, et al. (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-1476.
16. Mellman I, Warren G (2000) The road taken: past and future foundations of membrane traffic. Cell 100: 99-112.
17. Walter P, Gilmore R, Blobel G (1984) Protein translocation across the endoplasmic reticulum. Cell 38: 5-8.
18. Jurgens G, Geldner N Protein (2002) Protein secretion in plants: from the trans-Golgi network to the outer space. Traffic 3: 605-613.
19. Prudovsky I, Tarantini F, Landriscina M, Neivandt D, Soldi R, et al. (2008) Secretion without Golgi. J Cell Biochem 103: 1327-1343.
20. Nickel W (2003) The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur J Biochem 270: 2109-2119.
21. Simpson RJ, Mathivanan S (2012) Extracellular microvesicles: the need for internationally recognised nomenclature and stringent purification criteria. J Proteomics Bioinform 5.
22. Mathivanan S, Lim JW, Tauro BJ, Ji H, Moritz RL, Simpson RJ, et al. (2010) Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol Cell Proteomics 9: 197-208.
23. Mathivanan S, Ji H, Simpson RJ (2010) Exosomes: Extracellular organelles important in intercellular communication. J Proteomics 73: 1907-1920.
24. Hess C, Sadallah S, Hefti A, Landmann R, Schifferli JA (1999) Ectosomes Released by Human Neutrophils Are Specialized Functional Units. J Immunol 163: 4564-4573.
25. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, et al. (2008) Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10: 619-624.
26. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ (1999) Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 94: 3791-3799.
27. Cocucci E, Racchetti G, Meldolesi J (2009) Shedding microvesicles: artefacts no more. Trends Cell Biol 19: 43-51.
28. Arribas J, Borroto A (2002) Protein ectodomain shedding. Chem Rev 102: 4627-4638.
29. Sanderson MP, Keller S, Alonso A, Riedle S, Dempsey PJ, et al. (2008) Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem 103: 1783-1797.
30. Stoeck A, Keller S, Riedle S, Sanderson MP, Runz S, et al. (2006) A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J 393: 609-618.
31. Nickel W (2005) Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. Traffic 6: 607-614.
32. Nickel W (2007) Unconventional secretion: an extracellular trap for export of fibroblast growth factor 2. J Cell Sci 120: 2295-2299.
33. Zehe C, Engling A, Wegehingel S, Schafer T, Nickel W (2006) Cell-surface heparan sulfate proteoglycans are essential components of the unconventional export machinery of FGF-2. Proc Natl Acad Sci U S A 103: 15479-15484.
34. Denny PW, Gokool S, Russell DG, Field MC, Smith DF (2000) Acylationdependent protein export in Leishmania. J Biol Chem 275: 11017-11025.
35. Stegmayer C, Kehlenbach A, Tournaviti S, Wegehingel S, Zehe C, et al. (2005) Direct transport across the plasma membrane of mammalian cells of Leishmania HASPB as revealed by a CHO export mutant. J Cell Sci 118: 517-527.
36. Goldenberg DM, Sharkey RM, Primus FJ (1976) Carcinoembryonic antigen in histopathology: immunoperoxidase staining of conventional tissue sections. J Natl Cancer Inst 57: 11-22.
37. Smith TJ, Davidson NE, Schapira DV, Grunfeld E, Muss HB, et al. (1999) American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 17: 1080-1082.
38. Marrelli D, Roviello F, De Stefano A, Farnetani M, Garosi L, et al. (1999) Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 57: 55-62.
39. Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E (2000) The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology. 47: 1750-1752.
40. Teschendorff AE, Caldas C (2009) The breast cancer somatic 'muta-ome': tackling the complexity. Breast Cancer Res 11: 301.
41. Wu CC, Chen HC, Chen SJ, Liu HP, Hsieh YY, Yu CJ, et al. (2008) Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 8: 316-332.
42. Kulasingam V, Diamandis EP (2007) Proteomics analysis of conditioned media from three breast cancer cell lines: A mine for biomarkers and therapeutic targets. Mol Cell Proteomics 6: 1997-2011.
43. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
44. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
45. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
46. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, et al. (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 107: 18545-18550.
47. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, et al. (2007) Genetic progression and the waiting time to cancer. PLoS Comput Biol 3: e225.
48. Wang Q, Chaerkady R, Wu J, Hwang HJ, Papadopoulos N, et al. (2011) Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A 108: 2444-2449.
49. Mathivanan S, Ji H, Tauro BJ, Chen YS, Simpson RJ (2012) Identifying mutated proteins secreted by colon cancer cell lines using mass spectrometry. J Proteomics.
50. Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422: 198-207.
51. UniProt-Consortium (2010) The Universal Protein Resource (UniProt) in 2010. Nucleic Acids Res 38: D142-148.
52. Xi H, Park J, Ding G, Lee YH, Li Y (2009) SysPIMP: the web-based systematical platform for identifying human disease-related mutated sequences from mass spectrometry. Nucleic Acids Res 37: D913-920.
53. Cargile BJ, Bundy JL, Stephenson JL Jr. (2004) Potential for false positive identifications from large databases through tandem mass spectrometry. J Proteome Res 3: 1082-1085.
54. Mathivanan S (2012) Exosomes and shedding microvesicles are mediators of intercellular communication: how do they communicate with the target cells? J Biotechnol Biomater 2: e110.
55. Simpson RJ, Jensen SS, Lim JW (2008) Proteomic profiling of exosomes: current perspectives. Proteomics 8: 4083-4099.
56. van Niel G, Porto-Carreiro I, Simoes S, Raposo G (2006) Exosomes: a common pathway for a specialized function. J Biochem 140: 13-21.
57. Simpson RJ, Lim JW, Moritz RL, Mathivanan S (2009) Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6: 267-283.
58. Thery C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9: 581-593.
59. Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13-21.
60. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, et al. (2009) Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 100: 1603-1607.
61. Hanahan D, Weinberg RA (2000)The hallmarks of cancer. Cell 100: 57-70.
62. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH (2009) Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10: 42-46.
63. Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, et al. (2009) Proteomic and immunologic analyses of brain tumor exosomes. FASEB J 23: 1541-1557.